source
- Novo Nordisk signs $2.6 billion deal with China's Hengrui for oral GLP-1/GIP candidateNovo Nordisk announced a licensing agreement with Chinese drugmaker Hengrui Pharmaceuticals, paying $300 million upfront for rights to a preclinical GLP-1/GIP dual-receptor agonist. The candidate,…
- Lilly's triple-agonist retatrutide drives up to 18.8% weight loss, over half of patients fall below obesity thresholdAt the EASD Annual Meeting in Milan, Eli Lilly presented data on its triple‑agonist retatrutide. The trial involved participants with obesity and type 2 diabetes and showed weight reductions of up…